- Home
- QURE vs RLAY Comparison
QURE vs RLAY Comparison
Compare QURE & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- RLAY
- Stock Information
- Founded
- QURE 1998
- RLAY 2015
- Country
- QURE Netherlands
- RLAY United States
- Employees
- QURE N/A
- RLAY N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QURE Health Care
- RLAY Health Care
- Exchange
- QURE Nasdaq
- RLAY Nasdaq
- Market Cap
- QURE 860.8M
- RLAY 723.1M
- IPO Year
- QURE 2007
- RLAY 2020
- Fundamental
- Price
- QURE $15.18
- RLAY $4.91
- Analyst Decision
- QURE Strong Buy
- RLAY Strong Buy
- Analyst Count
- QURE 8
- RLAY 10
- Target Price
- QURE $33.00
- RLAY $20.11
- AVG Volume (30 Days)
- QURE 1.2M
- RLAY 2.9M
- Earning Date
- QURE 02-26-2025
- RLAY 02-20-2025
- Dividend Yield
- QURE N/A
- RLAY N/A
- EPS Growth
- QURE N/A
- RLAY N/A
- EPS
- QURE N/A
- RLAY N/A
- Revenue
- QURE $28,587,000.00
- RLAY $10,006,000.00
- Revenue This Year
- QURE $153.92
- RLAY N/A
- Revenue Next Year
- QURE N/A
- RLAY N/A
- P/E Ratio
- QURE N/A
- RLAY N/A
- Revenue Growth
- QURE N/A
- RLAY N/A
- 52 Week Low
- QURE $3.73
- RLAY $3.50
- 52 Week High
- QURE $19.18
- RLAY $11.16
- Technical
- Relative Strength Index (RSI)
- QURE 52.73
- RLAY 53.29
- Support Level
- QURE $13.70
- RLAY $3.50
- Resistance Level
- QURE $15.18
- RLAY $5.99
- Average True Range (ATR)
- QURE 1.07
- RLAY 0.54
- MACD
- QURE -0.54
- RLAY 0.06
- Stochastic Oscillator
- QURE 29.76
- RLAY 49.40
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).